Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-FND, Zevalin, and Maintenance Rituximab in High-Risk Follicular Lymphoma
NCT00290511Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2004
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Time to Progression at 10 years. Started Jun 2004; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00290511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290511.